Upload Avatar (500 x 500)
Yu Lei Zhao
zhaoyl@fudan.edu.cn
English, Chinese
Shanghai
Fudan University
Basic Medical Sciences
  • 2011.09-2016.06 Ph.D. in Pathology and Molecular Medicine: Queen's University, Canada
  • 2006.09-2011.06 Dual Bachelor's in Science and Medicine: Jilin University, China
  • 2022.12-Present - Fudan University - Young Researcher, Doctoral Supervisor
  • 2018.10-2022.11 - Sloan Kettering Cancer Center, USA - Research Associate
  • 2016.08-2018.08 - Queen's University, Canada - Postdoctoral Researcher
  • 2010.05-2011.05 - National Institute of Biological Sciences, Beijing - Undergraduate Thesis Intern
  • 2022: TDI ResMed Scholar
  • 2021: Charles H. Revson Senior Biomedical Research Scholar
  • 2021: MSK Society Scholar
  • 2016: CIHR/Terry Fox Foundation Interdisciplinary Award
  • 2016: Queen's University Outstanding Ph.D. Thesis
  • 2015: Queen's University Principal's Award
  • 2015: CIHR Research Competition Gold Medal
  • 2014: Chinese Government Award for Outstanding Self-financed Students Abroad
  • 2011-2015: Canadian Government Scholarship
  • 2013: Robert Kisilevsky Academic Presentation Award
  • 2011: Robert Kisilevsky Research Fund
  • 2008-2009: National Scholarship
  • 2007-2008: National Scholarship
  • 2008: National College English Competition Special Prize
  • 2009-2010: National Inspirational Scholarship
  • 2006-2007: National Inspirational Scholarship
  • 2006-2007: Jilin University First-Class Scholarship
  • 2006-2010: Jilin University Outstanding Student
Mechanisms of cell-autonomous and non-autonomous regulation in cancer development and drug resistance
Screening and identification of drug targets for cancer therapy
Development of small molecule drugs based on targets
  • Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS, Schulze CJ*, Seamon KJ*, Zhao Y* (co-first author), Yang YC, Cregg J, et al., 2023
  • Diverse alterations associated with resistance to KRAS(G12C) inhibition, Zhao Y*, Murciano-Goroff YR*, J. Russell Lipford^, Bob T. Li^ and Piro Lito^, 2021
  • Rapid non-uniform adaptation to conformation-specific KRASG12C inhibition, Xue J*, Zhao Y* (co-first author), Aronowitz J, Vides A, Qeriqi B, Kim DS, Stanchina E, Riely G, Mazutis L, Risso D and Lito P, 2020
  • Suppressing nucleotide exchange to inhibit KRAS-mutant tumors, Zhao Y, Xue J, Lito P, 2021
  • Pan-KRAS inhibitor disables oncogenic signalling and tumour growth, Kim D*, Herdeis L*, Rudolph D*, Zhao Y, Böttcher J, Vides A, et al., 2023
  • KRAS oncoprotein inactivation through enhanced GTPase activity, Li C, Vides A, Kim DS, Xue J, Zhao Y, Lito P, 2021
  • YAP-induced resistance of cancer cells to antitubulin drugs is modulated by a Hippo-independent pathway, Zhao Y, Khanal P, Savage P, She Y, Cyr TD, Yang X, 2014
Cancer Drug Resistance Cell-Autonomous Non-Autonomous Regulation Drug Targets Screening Identification Small Molecule Drugs Development

Contact us

Let's talk!
* Required
* Required
* Required
* Invalid email address
By submitting this form, you agree that IoT ONE may contact you with insights and marketing messaging.
No thanks, I don't want to receive any marketing emails from IoT ONE.
Submit

Thank you for your message!
We will contact you soon.